Osteoprotegerin (OPG): A potential biomarker for adverse cardiovascular events in stable coronary artery disease.
Syed Muhammad Muneeb AkhtarAzzam AliAreeba FareedJina HasanPublished in: Health science reports (2024)
OPG's role in bone health and immune regulation has expanded to potential use as a biomarker for adverse cardiovascular events in stable coronary artery disease (CAD) patients. Despite limitations, its association with cardiovascular risks highlights its importance in risk assessment and personalized interventions.
Keyphrases
- cardiovascular events
- coronary artery disease
- human health
- risk assessment
- percutaneous coronary intervention
- coronary artery bypass grafting
- end stage renal disease
- cardiovascular disease
- chronic kidney disease
- healthcare
- public health
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- prognostic factors
- bone mineral density
- mental health
- patient reported outcomes
- inflammatory response
- heavy metals
- toll like receptor
- heart failure
- electronic health record
- left ventricular
- adverse drug
- bone regeneration
- health promotion